Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups : real-world XALOC-1 programme
Copyright ©The authors 2024. For reproduction rights and permissions contact permissionsersnet.org..
BACKGROUND: Pivotal Phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection.
METHODS: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48 weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps).
RESULTS: Of 1002 patients analysed, 380 were biologic-experienced. At Week 48, 71.3% were exacerbation-free (versus 17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130/274) eliminated their use by Week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed.
CONCLUSION: In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The European respiratory journal - (2024) vom: 04. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jackson, David J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1183/13993003.01521-2023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370645820 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370645820 | ||
| 003 | DE-627 | ||
| 005 | 20240405234535.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/13993003.01521-2023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM370645820 | ||
| 035 | |a (NLM)38575162 | ||
| 035 | |a (PII)2301521 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jackson, David J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups |b real-world XALOC-1 programme |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright ©The authors 2024. For reproduction rights and permissions contact permissionsersnet.org. | ||
| 520 | |a BACKGROUND: Pivotal Phase 3 trials and real-world studies have demonstrated benralizumab's overall efficacy and safety in severe eosinophilic asthma (SEA). Additional large-cohort data are needed to confirm its real-world effectiveness in SEA according to previous biologic use and key baseline characteristics important for treatment selection | ||
| 520 | |a METHODS: XALOC-1 is a large, multinational, retrospective, observational, real-world study programme of benralizumab in adults with SEA. This 48-week integrated analysis assessed annualised exacerbation rate (AER), maintenance oral corticosteroid (mOCS) use, asthma symptom control and lung function during a 12-month baseline period and up to 48 weeks after benralizumab initiation. Subgroup analyses were based on previous biologic use and key baseline clinical characteristics (mOCS use, blood eosinophil count, exacerbation history, age at asthma diagnosis, fractional exhaled nitric oxide level and presence of atopy and chronic rhinosinusitis with nasal polyps) | ||
| 520 | |a RESULTS: Of 1002 patients analysed, 380 were biologic-experienced. At Week 48, 71.3% were exacerbation-free (versus 17.2% at baseline); relative reduction in AER was 82.7% overall and 72.9% in biologic-experienced patients; rates were maintained across all key clinical characteristic subgroups. Of patients using mOCS at baseline (n=274), 47.4% (130/274) eliminated their use by Week 48; the mean reduction from baseline in daily dose was 51.2% and, notably, 34.9% in biologic-experienced patients (n=115). Clinically significant improvements in asthma symptom control and lung function were observed | ||
| 520 | |a CONCLUSION: In this large, real-world programme, SEA patients treated with benralizumab had substantial improvements in clinical outcomes irrespective of previous biologic use and key clinical characteristics important to therapeutic decision-making in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Pelaia, Girolamo |e verfasserin |4 aut | |
| 700 | 1 | |a Emmanuel, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Trung N |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, David |e verfasserin |4 aut | |
| 700 | 1 | |a Shih, Vivian H |e verfasserin |4 aut | |
| 700 | 1 | |a Shavit, Anat |e verfasserin |4 aut | |
| 700 | 1 | |a Arbetter, Douglas |e verfasserin |4 aut | |
| 700 | 1 | |a Katial, Rohit |e verfasserin |4 aut | |
| 700 | 1 | |a Rabe, Adrian Paul J |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia Gil, Esther |e verfasserin |4 aut | |
| 700 | 1 | |a Pardal, Marisa |e verfasserin |4 aut | |
| 700 | 1 | |a Nuevo, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Watt, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Boarino, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Kayaniyil, Sheena |e verfasserin |4 aut | |
| 700 | 1 | |a Chaves Loureiro, Cláudia |e verfasserin |4 aut | |
| 700 | 1 | |a Padilla-Galo, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Nair, Parameswaran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d 1989 |g (2024) vom: 04. Apr. |w (DE-627)NLM012664782 |x 1399-3003 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:04 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/13993003.01521-2023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 04 |c 04 | ||